Advertisements

Nepafenac Alcon

Quick links to important sections

Nepafenac Alcon

Advertisements
Advertisements

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Advertisements

Overview of Nepafenac Alcon

Property Description
Active ingredient Nepafenac (Parent Prodrug)
Form Ophthalmic Suspension (Eye Drops)
Pharmacological class Non-steroidal Anti-inflammatory Drug (NSAID) / Prodrug
General Purpose Anti-inflammatory and Analgesic Relief
Origin Synthetic

Nepafenac Alcon refers to a specialized pharmaceutical entity that is classified as a prescription-only medication primarily manufactured by Alcon. The medication is formulated as a sterile ophthalmic suspension, meaning it is a liquid eye drop preparation specifically designed for topical ocular administration to the surface of the eye. Its unique action hinges on its chemical classification as a derivative of phenylacetic acid.


What Type of Medicine is Nepafenac Alcon?

Nepafenac is fundamentally categorized as an NSAID prodrug, a dual classification essential for its function. An NSAID is a class of medicine known for reducing pain and inflammation. The prodrug status, which is its key differentiating factor, means the administered compound itself is initially inactive; it is a synthetic compound that requires metabolic conversion by enzymes within the eye's tissues to become the therapeutically active substance, Amfenac. This bioactivation process allows the relatively non-polar Nepafenac molecule to achieve superior corneal penetration compared to many other ophthalmic NSAIDs.


What is the General Purpose of Nepafenac Eye Drops?

The general purpose of Nepafenac is to provide localized anti-inflammatory and analgesic (pain-relieving) action. The active metabolite, Amfenac, functions as a potent cyclooxygenase inhibitor, blocking the production of chemical mediators called prostaglandins that are directly responsible for causing swelling, pain, and redness. Clinically, Nepafenac is recognized for its use in patients undergoing specific eye procedures. This interruption of the inflammatory cascade is the core function for which the drug entity, Nepafenac, is applied, providing a targeted approach to managing postoperative ocular inflammation.

Regulatory References

  1. Nepafenac Ophthalmic: MedlinePlus Drug Information
  2. NEVANAC- nepafenac suspension/ drops - DailyMed - NIH
  3. Nevanac | European Medicines Agency (EMA)
Advertisements

What side effects are possible with Nepafenac Alcon?

Official Regulatory Safety Profile

Nepafenac ophthalmic suspension's safety profile is defined by officially documented adverse reactions categorized by frequency and the physiological system affected. The majority of documented effects relate to the Eye Disorders system, reflecting the medication’s topical application. Adverse reactions classified as Common in regulatory documents include decreased visual acuity, increased intraocular pressure, and foreign body sensation. Effects classified as Uncommon or Rare may involve punctate keratitis, headache, dizziness, and hypersensitivity reactions [EMA, FDA].

Documented Safety Constraints

Serious adverse reactions officially noted are primarily linked to the cornea, encompassing the potential for corneal thinning, epithelial breakdown, and in severe cases, sight-threatening events such as corneal perforation and ulcerative keratitis. As a non-steroidal anti-inflammatory drug (NSAID), Nepafenac may also present an NSAID class effect of potentially increased ocular bleeding.

Risk patterns are tied to exposure duration; prolonged use of topical NSAIDs can increase the risk and severity of corneal adverse reactions. Furthermore, certain high-risk patient groups, specifically those with diabetes mellitus or a history of complicated ocular surgery, are noted in labeling as being at increased risk for these corneal complications. The label also specifies that concomitant use with topical steroids may slow or delay corneal healing [DailyMed].

Advertisements

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory profile for Nepafenac ophthalmic suspension emphasizes the drug’s minimal systemic absorption, which structures the information available regarding overdose scenarios.

Documented Overdose Profile

Based on regulatory documentation, toxic effects are generally classified as unlikely to occur following either a topical ocular overdose or accidental oral ingestion. This determination is based on the drug’s low systemic exposure profile.

  • Clinical Manifestations: Specific overdose symptoms are not documented in the official prescribing information, and the product labeling notes that there is no experience of overdose from ocular use. The application of more product than recommended is categorized as unlikely to lead to unwanted side effects.
  • Serious Outcomes: Regulators state that there is practically no risk of adverse effects associated with accidental oral ingestion due to the low absorption rate.
  • Antidote Information: No specific antidote is described in the official regulatory documentation.

Regulatory-Mandated Emergency Actions

The primary required actions are based on the route of potential overexposure:

  • Ocular Overuse: If more of the suspension than recommended is used in the eye, the official guidance is to rinse the eye out with warm water.
  • Accidental Oral Ingestion: If accidental ingestion occurs, official guidance mandates that an individual should contact a health care practitioner, hospital emergency department, or regional Poison Control Centre immediately, regardless of whether or not symptoms are present. Seeking immediate assessment is the necessary action for this scenario.
Advertisements

Therapeutic Uses of Nepafenac Alcon

What Nepafenac Alcon Treats: Main Uses and Benefits

Nepafenac Alcon is a topical non-steroidal anti-inflammatory drug (NSAID) commonly used across conditions involving inflammatory or irritative processes following surgery. The medication may be part of symptomatic management across three key therapeutic domains, focusing strictly on indications related to cataract surgery.

The medication is used in areas where short-term symptom management is appropriate, particularly for the symptom clusters of ocular pain and inflammation following cataract surgery. This medication is considered relevant for easing symptoms related to physical discomfort, primarily addressing the acute pain and soreness that arises after eye procedures. Its use supports the patient during difficult episodes by easing distress, contributing to improved comfort during periods of heightened symptoms.

Nepafenac is also applied in clinical settings that involve acute symptom patterns to manage the symptoms that create noticeable physiological strain like eye redness and swelling. For high-risk groups, such as diabetic patients, it may assist with maintaining functional stability by playing a role in managing the risk of postoperative macular oedema (swelling in the central retina).


Quick Fact: Supportive Management for Postoperative Inflammation and Pain The medication is relevant for managing symptoms that cluster around postoperative discomfort and acute inflammation, including the reduction of redness, swelling, and pain following cataract procedures.

Regulatory References

  1. European Medicines Agency therapeutic overview
Advertisements

Eligibility and Restrictions for Use

Eligibility for Nepafenac Ophthalmic Suspension

Nepafenac is subject to official restrictions that determine which patients may use the medication. The drug is contraindicated and must not be used by individuals with a known hypersensitivity or allergy to nepafenac, any of its ingredients, or any other Nonsteroidal Anti-inflammatory Drugs (NSAIDs), including those who have experienced asthma, urticaria, or acute rhinitis following aspirin use.


Age-Related Eligibility

  • Allowed: Use is generally permitted for adults and pediatric patients 10 years of age and older.
  • Not Established: The safety and effectiveness of the ophthalmic suspension have not been established in children younger than 10 years of age, leading to their exclusion from the indicated population.
  • Geriatric Use: No overall differences in safety or effectiveness have been observed between elderly and younger adult patients.

Pregnancy and Other Restrictions

The use of Nepafenac is not recommended during late pregnancy because of the known effects of prostaglandin biosynthesis inhibitors on the fetal cardiovascular system. Caution is advised for nursing mothers and for patients with known bleeding tendencies or pre-existing conditions like diabetes mellitus, rheumatoid arthritis, or certain corneal diseases (e.g., dry eye syndrome or epithelial defects). Additionally, patients must not wear contact lenses during the course of treatment.

Advertisements

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile for Nepafenac Ophthalmic Suspension is primarily defined by pharmacodynamic effects and administration timing rules, reflecting the drug's localized ocular application and minimal systemic absorption.

Interaction Profile Summary

Interaction Type Interacting Agent Category Official Regulatory Statement
Pharmacodynamic Topical Corticosteroids Co-administration may increase the risk of delayed corneal healing or impaired repair.
Pharmacodynamic Agents Prolonging Bleeding Time (e.g., Oral Anticoagulants) Co-administration may increase the risk of hemorrhage in ocular tissues, including hyphema.
Administration Timing Other Topical Ophthalmic Medications Must be administered with at least 5 minutes of separation between applications.
Metabolic Potential CYP450 Inhibitors/Inducers Has a very low potential for systemic drug-drug interactions involving major CYP enzymes.

Officially documented data indicates that Nepafenac has a negligible risk of altering the exposure of other medicines through metabolism or protein binding. However, because the product is an NSAID, use is contraindicated in patients with known hypersensitivity to Nepafenac or other NSAIDs. Additionally, the concomitant use of Prostaglandin Analogues is not recommended by some regulatory bodies due to limited data regarding their combined effect.

Advertisements

Mechanism of Action

The action of Nepafenac is a highly localized, two-step pharmacodynamic mechanism designed to interrupt the primary biochemical drivers of inflammation within the eye.


️ Prodrug Bioactivation and Enzyme Inhibition

The mechanism begins as Nepafenac (the parent compound) undergoes rapid hydrolysis by hydrolase enzymes found in the eye's tissues, converting it into the pharmacologically active metabolite, Amfenac. Amfenac functions as a non-selective inhibitor of the Cyclooxygenase ( COX-1 and COX-2) enzymes. This initial bioactivation step supports the localized generation of the molecule responsible for the subsequent physiological changes.


⬇️ Modulation of Prostaglandin Synthesis

By inhibiting COX enzyme activity, Amfenac blocks the conversion of arachidonic acid into pro-inflammatory mediators, primarily prostaglandins such as PGE2. The resulting reduction in prostaglandin levels within ocular tissues leads to a cascading physiological effect that modulates blood-aqueous barrier permeability and reduces the production of mediators associated with vasodilation and increased vascular permeability.


️ Attenuation of Nociceptive Signaling

The reduction of PGE2 concentration produces an anti-nociceptive functional consequence by decreasing the sensitization of pain-sensing nerves (nociceptors). This specific physiological change alters nociceptor excitability, influencing signal transmission. The mechanism engages in targeted pathway interference to modulate physiological responses.

Advertisements

Dosage and Administration Information

Administration Scope

The administration of Nepafenac ophthalmic suspension is restricted to Topical Ocular Administration, meaning it is applied directly to the conjunctival sac and is not for injection or oral use. Use is strictly time-bound to the surgical procedure, commencing one day prior to cataract surgery and requiring an additional single dose 30 to 120 minutes before the operation.

Labeled Dosing and Frequency

The specific dosing regimen is determined by the strength of the suspension. The 0.1% strength is typically administered as one drop three times daily (TID) in the affected eye(s), while the 0.3% strength is administered once daily (QD). This standard dosing applies to adults and to pediatric patients 10 years of age and older. If a scheduled drop is missed, the official procedure is to apply a single drop as soon as possible and return to the normal schedule; double doses should not be used to compensate.

Course Duration and Constraints

Standard postoperative treatment continues for the first two weeks following surgery. This duration may be extended to three weeks post-surgery or, for specific usage in diabetic patients, up to 60 days. Proper administration requires the container to be shaken well before each use.

Special Procedural Conditions mandate that the medication should not be administered while wearing contact lenses. Furthermore, when using multiple topical eye products concurrently, a minimum interval of at least 5 minutes must separate the instillations.

Connection to the Official Protocol

The established protocol defines a mandatory topical ocular regimen with a fixed, surgical-event-based timeline. These rules establish precise strength-dependent QD or TID dosing, along with specific preparatory and scheduling conditions that govern the sequence of application and adherence to the time-bound use protocol.

Advertisements

Recent Clinical Evidence

Research evidence / Overview of studies for Nepafenac Alcon


Evidence for Use in Postoperative Ocular Pain and Inflammation

Research has explored the use of Nepafenac in several short-term Randomized Controlled Trials (RCTs) following cataract surgery. These studies typically included Nepafenac and compared it against an inactive vehicle (a 'dummy' eye drop). Researchers primarily examined outcomes related to physical discomfort (pain) and outcomes linked to inflammatory or irritative states (swelling and redness in the front part of the eye).

Studies examined the time it took for patients to reach minimal pain levels and monitored differences between the Nepafenac group and the vehicle group. Similarly, research examined changes measured during the study period related to inflammation in the front part of the eye. Some findings indicate patterns where the rate of change in certain inflammation metrics was observed sooner in the Nepafenac group.

While the findings from multiple RCTs contribute to a high evidence level for this use, the key research is predominantly focused on the immediate two-week period following surgery. This means that long-term effects are not fully established. Comparative evidence is lacking for extensive head-to-head trials against all available competing topical non-steroidal anti-inflammatory drug (NSAID) regimens.


Evidence for studies exploring the risk of Macular Oedema in Diabetic Patients

This part will focus on the research base exploring the risk of swelling in the central retina in a high-risk group: adult diabetic patients undergoing cataract surgery. The primary outcome examined data on the incidence of Postoperative Macular Oedema (ME), measured objectively using Optical Coherence Tomography (OCT) to track changes in central retinal thickness.

Research describes patterns related to the incidence of ME in the high-risk diabetic populations studied. Studies reported measurements of the percentage of patients who developed the criteria for macular oedema in both the Nepafenac group and the vehicle group over the observation period. The evidence base for this outcome is highly focused on the diabetic patient population, which means that results apply only to the populations studied.


Key Evidence Gaps and Areas of Uncertainty

Several limitations exist in the current evidence landscape. Primarily, there is limited information for long-term outcomes, as follow-up in most core trials was confined to the immediate post-operative period (two to three weeks) or the intermediate period (up to 90 days). The evidence for the prevention of macular oedema is heavily weighted toward the diabetic patient subgroup, meaning data for non-diabetic individuals remains insufficient for this outcome. Research does not determine whether an individual will respond similarly to the group patterns observed.

Advertisements

Frequently Asked Questions (FAQ)

Common questions about Nepafenac Alcon (FAQ)

Q: Is Nepafenac Alcon the same as other eye drops for surgery?

A: Nepafenac is classified as a Non-Steroidal Anti-inflammatory Drug (NSAID) prodrug, which is one type of medicine used following eye surgery. This classification is different from other drops, such as corticosteroids (steroids). Official documents note that using Nepafenac with certain steroid drops may increase the risk of delayed healing in the eye.

Q: How quickly is Nepafenac Alcon expected to start working?

A: Clinical studies show that the active form of the medicine is typically detectable in the eye's tissues about 15 to 30 minutes after applying the drop. The medication is designed to be used as part of a scheduled course, often beginning before the surgery, to manage inflammation and pain throughout the post-operative period.

Q: How is Nepafenac Alcon different from prescription drops that reduce swelling?

A: Nepafenac is an NSAID, meaning it works by directly blocking the body’s production of chemical messengers called prostaglandins that cause pain and swelling. Other drops, such as steroids, reduce swelling through a broader mechanism that suppresses the immune system's general inflammatory response.

Q: Can Nepafenac Alcon be used long-term?

A: Official treatment protocols define a course of use that generally lasts for two to three weeks after surgery, with possible extension up to 60 days for specific high-risk patients. Regulatory warnings indicate that using topical NSAIDs for an excessively prolonged time may increase the risk of serious side effects affecting the cornea (the clear front surface of the eye).

Q: Is it safe to use Nepafenac Alcon with artificial tears?

A: Official instructions mandate a minimum interval of at least 5 minutes between each application when using multiple eye drops, including products like artificial tears. This rule is in place to ensure the medicine stays on the eye long enough to work and is not washed away.

Q: What research evidence supports the use of Nepafenac Alcon after eye surgery?

A: Clinical studies submitted to regulatory bodies showed that Nepafenac was more effective than an inactive control (a placebo drop) at both clearing ocular inflammation and eliminating pain associated with cataract surgery. This evidence supports its approved use.

Q: Can pregnant women or those who are breastfeeding use Nepafenac Alcon?

A: The medicine is not recommended during late pregnancy because of potential risks to the fetal cardiovascular system from this class of drugs. Official documents also advise caution for nursing mothers, as it is unknown if the medicine passes into breast milk.

Q: Does Nepafenac Alcon have an expiration date once the bottle is opened?

A: Yes, once the bottle is opened, the medicine must be discarded after 4 weeks. This in-use period is officially set to help maintain the sterility and stability of the product.

Q: Are there common mistakes patients make when applying eye drops like Nepafenac Alcon?

A: Regulatory guidance includes several rules intended to help prevent misuse and contamination. These rules emphasize the importance of shaking the bottle well before each use and ensuring the dropper tip does not touch the eye or any other surface.

Q: Is Nepafenac Alcon used for red eye?

A: The medicine is indicated for treating inflammation and pain that follow eye surgery. Since redness (ocular hyperemia) is a common visible sign of inflammation, treating the underlying inflammatory process is expected to help reduce the associated redness.

Q: Is it normal to feel a stinging sensation after putting in Nepafenac Alcon?

A: Adverse events reported in official safety documents include various temporary eye sensations. These reports indicate that a temporary stinging or burning sensation upon application has been associated with the use of the drops.

Q: What should I do if my symptoms don't get better while using Nepafenac Alcon?

A: Official patient information advises that if you experience worsening symptoms or if your condition does not improve within a few days of use, a healthcare professional should be consulted.

Q: Does Nepafenac Alcon have a generic version available?

A: Government records pertaining to drug availability indicate that the specific brand formulation is protected by patents. Generic versions typically become available only after the relevant patents for the product have expired.

Q: Does using Nepafenac Alcon affect driving or vision right after use?

A: As with any eye drops, temporary blurred vision or other visual disturbances may occur immediately after the drops are put in. Official guidance advises waiting until vision clears before activities like driving or operating machinery.

Q: What is the risk of an allergic reaction to Nepafenac Alcon?

A: The risk of a serious allergic reaction (hypersensitivity) to Nepafenac is described in official safety documents. Such events are generally classified as Uncommon or Rare adverse reactions.

Q: What are the signs that Nepafenac Alcon is working correctly?

A: The medicine's purpose is to manage pain and inflammation following surgery. Signs that the treatment is functioning as intended include a measured reduction in eye pain and a decrease in the clinical signs of inflammation, such as swelling and redness.

Q: Does alcohol consumption affect the safety of Nepafenac Alcon?

A: Because this medicine is applied topically to the eye, very little is absorbed into the rest of the body. Official regulatory documents do not document a specific interaction between the eye drops and alcohol consumption.

Q: Are headaches a common side effect of Nepafenac Alcon?

A: According to the official safety profile, headache is reported as an Uncommon adverse reaction. This classification means it occurs in less than 1 out of every 100 people using the medication.

Q: Is it possible to become dependent on Nepafenac Alcon?

A: Official documents that govern the use and safety of the medication do not list dependency or addiction as a known side effect or warning associated with the use of Nepafenac ophthalmic suspension.

Q: Is Nepafenac Alcon a preventative medicine?

A: The medicine is primarily prescribed to treat pain and inflammation that occur after surgery. However, the official dosing schedule often begins one day prior to the procedure, which indicates an intent to modify the inflammatory response before it fully develops.

Q: Why do official documents caution against overuse of topical NSAIDs like Nepafenac Alcon?

A: The specific caution against prolonged use is due to the potential for an increased risk and severity of corneal adverse reactions. These serious events can include the breakdown or thinning of the cornea, which can affect vision.

Q: Are the safety profiles of the different strengths of Nepafenac Alcon the same?

A: For the two main strengths, 0.1% and 0.3%, the overall safety profile is generally similar according to regulatory reviews. However, due to the higher exposure to the active ingredient in the 0.3% concentration, some regulators note a potentially higher risk of ocular bleedings (hemorrhage) in the eye.

Q: What is the purpose of the NSAID class of drugs in ophthalmology?

A: The main purpose of the Non-Steroidal Anti-inflammatory Drug (NSAID) class in eye care is to provide both anti-inflammatory and analgesic (pain-relieving) effects locally. They achieve this by blocking the production of pro-inflammatory chemicals like prostaglandins.

Q: Do research findings consistently show benefits for Nepafenac Alcon in post-operative care?

A: The medicine was approved based on studies that demonstrated it was more effective than an inactive control in its ability to clear ocular inflammation and eliminate pain associated with cataract surgery, which supports its indicated use.

Q: What is the difference between Nepafenac Alcon and a steroid eye drop?

A: Nepafenac is an NSAID that blocks the production of inflammatory mediators (prostaglandins) at the source. Steroid eye drops, which are a different drug class, work by broadly suppressing the inflammatory immune response in the eye to reduce swelling.

Q: Can Nepafenac Alcon cause blurry vision immediately after application?

A: Yes, regulatory information advises that temporary blurred vision or other visual disturbances are common effects that can occur right after the drops are put in, which is common with many eye suspensions.

Q: What ingredients are in Nepafenac Alcon besides the main medicine?

A: The suspension contains inactive ingredients, called excipients, that help formulate the drop. Notably, it contains the preservative benzalkonium chloride, which is listed in official documents and is known to potentially discolour soft contact lenses.

Advertisements

How should Nepafenac Alcon be stored and disposed of?

How to Store and Dispose of Nepafenac Ophthalmic Suspension

Official regulatory information mandates specific conditions for storing and discarding nepafenac ophthalmic suspension to maintain its stability.


Storage Requirements

  • Temperature: The product must be stored at room temperature, typically defined as 2 C to 25 C (36 F to 77 F), and must not be stored above 30 C.
  • Protection: The suspension must not be frozen and should be kept away from excessive heat, moisture, and direct light.
  • Container: The container must be kept tightly closed when not in use and stored out of the sight and reach of children.

Stability and Disposal

  • In-Use Period: The medicine must be discarded 4 weeks after the bottle is first opened.
  • Disposal: Unused or expired medication must not be thrown away via wastewater or household waste; disposal should follow instructions from a healthcare professional.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Nepafenac Alcon found in:

A-Z Index: